Event Update



July 15, 2010

Piramal Healthcare (NICPIR)

WHAT'S CHANGED...

PRICE TARGET	. Changed from Rs 595 to Rs 589
EPS of residual business (FY11E)	Rs 4.6
EPS of residual business (FY12E)	Rs 5.9
RATING	Unchanged

Diagnostic business off the shelf...

Piramal Healthcare has signed a definitive agreement to sell its diagnostic business to Super Ranbaxy Laboratories (SRL) for a consideration of Rs 600 crore. SRL is promoted by Malvinder and Shivinder Singh. Piramal will receive Rs 300 crore on closure of the deal and a final payment of Rs 300 crore after three years. The deal is valued at 3x the revenue of the diagnostics business and is expected to close by the end of Q3FY11. The diagnostics business contributed ~5.6% to the FY10 topline. The deal includes transfer of 107 laboratories, ~300 collection centres and ~450 employees to SRL. Post the deal, SRL will have the largest pathology and radiology network. Piramal will have 10% equity participation in SRL valued at Rs 135 crore, which it will exit after three years. We estimate the residual businesses will clock an EPS of ~Rs 5.9 in FY12E. Valuing the cash per share from Abbott and SRL at Rs 518 and residual business at Rs 71, we have arrived at a fair value of Rs 589 for PHIL, providing 17% upside from current levels. We maintain our BUY rating on the stock.

Highlights of the deal


PHIL has retained its CRAMS, global critical care, domestic API and vitamins/minerals business. The company is considering a special dividend post the deal. The company will look at acquisitions to complement the residual business and enter newer businesses.

Valuation

PHIL is set to receive US\$3.3 billion on NPV value from Abbott and Rs 600 crore from SRL. This works out to Rs 518 per share (post long-term capital gains taxed at 21.5%, book value adjustment and debt repayment of \sim Rs 1300 crore). The residual business is valued at Rs 71 (12x FY12E EPS). We have rated PHIL as **BUY** with a target price of Rs 589. With cash utilisation by the management post the deal we expect the stock to get re-rated, going forward.

Exhibit 1: Financial Summary									
(Rs Crore)	FY08	FY09	FY10	FY11E	FY12E				
Net Sales	2848.3	3281.1	3671.1	4102.8	4633.3				
EBITDA	517.1			843.5	977.7				
Net Profit	333.8			528.1	638.4				
EPS	16.0	15.1	23.1	25.3	30.5				
PE	32.0	33.8	22.2	20.2	16.7				
EV/EBITDA	21.8	20.5	16.1	13.9	11.8				
RoNW (%)	30.7	24.0	28.3	25.4	25.3				
RoCE (%)	24.6	17.7	18.8	20.9	22.7				

Source: Company, ICICIdirect.com Research



Key Financials				
(Rs Crore)	FY09	FY10	FY11E*	FY12E*
Net Sales	3281.1	3671.1	4102.8	4633.3
EBITDA	581.3	740.9	843.5	977.7
Net Profit	316.2	481.8	528.1	638.4

Valuation Summary	/			
	FY09	FY10	FY11E*	FY12E*
EPS (Rs)	15.1	23.1	25.3	30.5
PE (x)	33.3	21.9	19.9	16.5
Target PE (x)	38.9	25.5	23.3	19.3
EV to EBITDA (x)	20.3	15.9	13.7	11.7
Price to book (x)	8.0	6.2	5.0	4.2
RoNW (%)	24.0	28.3	25.4	25.3
RoCE (%)	17.7	18.8	20.9	22.7

* Will be revised post successful closure of deals

SLUCK UALA	
Market Capitalisation (Rs Crore)	10530.5
Debt (FY10), (Rs Crore)	1418.1
Cash (FY10), (Rs Crore)	138.2
EV (Rs Cr)	11810.4
52 week H/L	600/300
Equity capital (Rs Crore)	41.8
Face value (Rs)	2.0
MF Holding (%)	3.3
FII Holding (%)	26.1



Analyst's name

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Ashish Thavkar ashish.thavkar@icicisecurities.com



The deal

We have valued the residual business at Rs 71/share on FY12E earnings. We have valued the cash inflow from Abbott, including the upfront payment (US\$2.12 billion) and the discounted value of the annuity payments adjusted for debt repayment and book value and capital gains tax, at Rs 496/share. The deal with SRL has been valued at Rs 22/share while the residual business has been valued at 12xFY12E EPS of Rs 71/share. The combined value of the entity stands at Rs 589/share. We expect the stock to get rerated on account of deployment of cash by the management.

Exhibit 2: Deal structure				(F	s Crore)
	Piramal - Abb				
	Upfront				
Payment from Abbott (US\$ 2.12 bn)	9540	1800	1800	1800	1800
NPV, discounted at 15%	14679.0				
Adjusted for BV	13979.0				
Less Capital gains tax at 21.5%	3005.5				
Less Debt Repayment	1300.0				
Total Cash	10373.5				
Cash Per Share	496.3				
	Piramal - SI		1 6 0		
	Upfront	To be receiv	/ed aπer 3 y	ears	
Payment from SRL	300	300			
NPV, discounted at 15%	497.3				
Adjusted for BV	202.3				
Less Capital gains tax at 21.5%	43.5				
Total Cash	453.8				
Cash Per Share	21.7				
R	esidual busines	ss valuation			
FY12 estimated PAT	124.2				
FY12E EPS	5.9				
Target price at 12xFY12E EPS	71.3				
Target Price per share (post deal)	589,4				

Source: Company, ICICIdirect.com Research



Residual business to remain key focus

Post the deal with Abbott and SRL, PHIL has been left with the CRAMS, global critical care, domestic API and vitamins/minerals business. These businesses contributed ~40% to the FY10 topline. We expect a revamp in the international CRAMS business to lead the majority of the growth, going ahead. We expect the India-based assets to offset a decline in the international CRAMS business in the near term. The Abbott-PHIL and SRL-PHIL deal will lead to greater focus for PHIL to turn around its CRAMS business and drive the future growth of the critical care and the OTC businesses.

Exhibit 3: PHIL's business break-up									
(Rs Crore)	FY08	% share	FY09	% share	FY10	% share			
Sold-out Business									
Healthcare Solutions *	1291.4	45.0	1604.9	48.9	2000.2	54.5			
Diagnostics	98.5	3.4	169.0	5.1	206.4	5.6			
Residual Business									
Pharma Solutions	1008.1	35.2	1060.6	32.3	885.0	24.1			
From Assets in India	225.9	7.9	392.5	12.0	375.9	10.2			
From Assets o/s India	782.2	27.3	668.1	20.4	509.1	13.9			
Global Critical Care	119.4	4.2	131.6	4.0	327.7	8.9			
Others	350.2	12.2	315.0	9.6	251.7	6.9			
Total	2867.5	100.0	3281.1	100.0	3671.1	100.0			

Source: Company, ICICIdirect.com Research

* Retained domestic API and vitamins/minerals business

Valuation

In the contract manufacturing space, PHIL grew at a slower pace on account of control over the channel inventory by PHIL's CRAMS clients. We believe PHIL's CRAMS business will see a recovery in FY11 as innovator pharma companies come out of the current mode of inventory de-stocking. New orders from Pfizer will help revive Morepeth operations. We believe growth in the overseas CRAMS business will improve during FY11E. We expect the India-based assets to offset a decline in the international CRAMS business in the near term. We expect margin expansion from Minrad operations due to sales ramp up and better sourcing.

Going ahead, we expect the stock to get re-rated on account of a) future strategy and outlook b) incremental revenue from Minrad c) higher contribution of the CMG business and d) utilisation of cash. Margin improvement will be aided by a) higher realisation at Minrad and b) cost saving on account of closure of the Huddersfield facility.

PHIL is set to receive US\$3.3 billion on NPV value from Abbott and Rs 600 crore from SRL. This works out to Rs 518 per share (post long-term capital gains taxed at 21.5%, book value adjustment and debt repayment of ~Rs 1300 crore). The residual business is valued at Rs 71 (12x FY12E EPS). We have rated PHIL as **BUY** with a target price of Rs 589. With cash utilisation by the management post the deal we expect the stock to get re-rated, going forward.

Piramal Healthcare (NICPIR)



Alembic					Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%
Idirect Code	ALECHE	СМР	56	FY08	1003.2	8.0	7.0	8.1	32.6	19.1
		Target	41	FY09	1116.1	3.4*	16.8	9.8	14.0*	11.3
МСар	781.6	Upside (%)	-27	FY10	1138.2	3.0	19.1	10.1	11.7	9.7
•		,		FY11E	1223.9	4.1	13.8	8.6	14.5	11.3
Biocon	DIGGONI	0145		FV00	Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	BIOCON	CMP	303	FY09	1608.7	12.0	25.1	20.3	11.4	13.2
	0054.0	Target	335	FY10	2367.8	14.7	20.7	13.6	12.4	15.6
МСар	6054.0	Upside (%)	11	FY11E	2668.5	17.2	17.6	11.5	13.2	16.7
				FY12E	3039.6	20.4	14.9	9.6	13.9	17.6
Dishman					Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	DISHPHA	СМР	217	FY09	1062.4	18.2	11.9	9.3	20.9	13.6
		Target	218	FY10	915.4	14.6	14.9	12.1	15.0	9.1
МСар	1716.4	Upside (%)	1	FY11	1075.3	19.6	11.1	9.2	17.1	11.1
				FY12E	1256.5	21.4	10.1	7.8	16.4	11.9
IPCA Labs					Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	IPCLAB	СМР	294	FY09	1283.8	8.1	37.6	4.7	16.0	19.6
		Target	311	FY10	1559.6	16.4	18.4	3.7	23.7	20.5
МСар	3787.5	Upside (%)	6	FY11E	1878.0	19.9	15.2	3.0	23.1	22.5
-				FY12E	2237.2	23.9	12.7	2.3	22.4	24.1
D ¹ 111 141						500 (D.)			D B B B B B B B B B B	D. 05 (9()
Piramal Health	NICPIR	СМР	504	EVOO	Sales (Rs Cr) 3281.1	EPS (Rs) 15.1	PE(x) 33.3	EV/E (x) 20.3	RoNW (%) 24.0	RoCE (%)
Idirect Code	NICPIK		504 589	FY09 FY10						17.7
МСар	10530.5	Target Upside (%)	569 17	FY10 FY11E	3671.1 4102.8	23.1 25.3	21.9 19.9	15.9 13.7	28.3 25.4	18.8 20.9
wcap	10530.5	Opside (%)	17	FY11E FY12E	4633.3	25.3 30.5	19.9	13.7	25.4 25.3	20.9
				11125	4000.0	50.5	10.5	11.7	20.0	22.1
Sun Pharma					Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	SUNPHA	СМР	1744	FY09	4271.4	88.1	19.8	18.6	25.9	28.5
		Target	1644	FY10	4019.8	65.2	26.7	25.2	17.8	19.6
МСар	36128.6	Upside (%)	-6	FY11E	4464.8	71.7	24.3	22.3	16.8	18.8
				FY12E	5151.8	82.2	21.2	18.5	16.7	18.5
Glenmark					Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	GLEPHA	СМР	280	FY09	2093.0	7.7	36.5	21.0	19.4	16.4
		Target	325	FY10	2484.9	12.2	23.0	15.0	13.9	14.6
МСар	7542.0	Upside (%)	16	FY11E	2927.1	15.9	17.5	11.6	18.6	17.7
				FY12E	3390.1	21.7	12.9	9.2	20.9	20.3
Lupin					Salaa (Ba Cri)				DoNIA/ (9/)	Bace /0/)
Idirect Code	LUPIN	СМР	1875	FY08	Sales (Rs Cr) 2706.4	EPS (Rs) 49.8	PE(x) 37.7	EV/E (x) 37.4	RoNW (%) 31.9	RoCE (%) 22.2
	LOI IN	Target	2101	FY09	3775.9	61.3	30.6	25.7	35.6	23.6
МСар	16621.5	Upside (%)	12	FY10	4740.5	78.7	23.8	20.5	33.0	25.8
Moap	10021.5	opside (70)	12	FY11E	5930.3	93.0	20.2	15.5	27.2	25.4
				FY12E	6997.7	116.7	16.1	12.0	24.9	24.7
Unichem Labs			400	P 1/00	Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	UNILAB	CMP	489 511	FY09	735.2	30.0	16.3	12.4	22.3	23.2
MCar	1700.0	Target	511 4	FY10	765.5	36.9	13.3	9.5	23.3	25.7
МСар	1763.3	Upside (%)	4	FY11E FY12E	905.7 1057.8	42.1 51.1	11.6 9.6	7.7 6.2	22.4 23.0	26.1 26.9
				11126	1007.0	JI.I	3.0	0.2	Z3.U	26.9
Indoco Remedie	S				Sales (Rs Cr)	EPS (Rs)	PE(x)	EV/E (x)	RoNW (%)	RoCE (%)
Idirect Code	INDREM	СМР	475	FY09	350.6	25.6	18.6	13.2	11.3	10.9
		Target	403	FY10	398.3	34.2	13.9	11.1	13.3	11.1
МСар	583.5	Upside (%)	-15	FY11E	466.1	42.6	11.2	8.3	14.3	13.5
				FY12E	530.6	49.0	9.7	7.2	14.3	13.8



RATING RATIONALE

ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Add, Reduce, and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock.

Strong Buy: 20% or more; Buy: Between 10% and 20%; Add: Up to 10%; Reduce: Up to -10% Sell: -10% or more;

Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICIdirect.com Research Desk, ICICI Securities Limited, 7th Floor, Akruti Centre Point, MIDC Main Road, Marol Naka, Andheri (East) Mumbai – 400 093

research@icicidirect.com

ANALYST CERTIFICATION

We /I, Siddhant Khandekar CA INTER Ashish Thavkar MBA, FINANCE research analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the ICICI Securities Inc.

Disclosures:

ICICI Securities Limited (ICICI Securities) and its affiliates are a full-service, integrated investment banking, investment management and brokerage and financing group. We along with affiliates are leading underwriter of securities and participate in virtually all securities trading markets in India. We and our affiliates have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. Our research professionals provide important input into our investment banking and other business selection processes. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their dependent family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on reasonable basis, ICICI Securities, its subsidiaries and associated companies, their directors and employees ("ICICI Securities and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities form doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities is acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICIC Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment tervicies, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient shall dively evaluate the investment risks. The value and return of investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICIC Securities and affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities and its affiliates might have managed or co-managed a public offering for the subject company in the preceding twelve months. ICICI Securities and affiliates might have received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of public offerings, corporate finance, investment banking or other advisory services in a merger or specific transaction. ICICI Securities and affiliates expect to receive compensation from the companies mentioned in the report within a period of three months following the date of publication of the research report for services in respect of public offerings, corporate finance, investment banking or other advisory services in a merger or specific transaction. It is confirmed that *Siddhant Khandekar CA INTER Ashish Thavkar MBA, FINANCE* research analysts and the authors of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Our research professionals are paid in part based on the profitability of ICICI Securities, which include earnings from Investment Banking and other business.

ICICI Securities or its subsidiaries collectively do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

It is confirmed that Siddhant Khandekar CA INTER Ashish Thavkar MBA, FINANCE research analysts and the authors of this report or any of their family members does not serve as an officer, director or advisory board member of the companies mentioned in the report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. ICICI Securities and affiliates may act upon or make use of information contained in the report prior to the publication thereof.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.